Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Duopharma Biotech BhdXKLS:7148 -0.81%79 Debt-to-Equity is 0.64 as of Mar. 2026, which is 19% above its 10-year median of 0.54. GuruFocus rates XKLS:7148 with a GF Score™ of 79/100 and a GF Value™ of RM1.55 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 812 Drug Manufacturers companies, Duopharma Biotech Bhd ranks worse than 76.48% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Duopharma Biotech Bhd's Debt-to-Equity or its related term are showing as below:
XKLS:7148'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.24 Med: 0.54 Max: 0.87
Current: 0.64
During the past 13 years, the highest Debt-to-Equity Ratio of Duopharma Biotech Bhd was 0.87. The lowest was 0.24. And the median was 0.54.
XKLS:7148's Debt-to-Equity is ranked worse than 76.48% of 812
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs XKLS:7148: 0.64
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Duopharma Biotech Bhd Debt-to-Equity Related Terms
Duopharma Biotech Bhd Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Duopharma Biotech Bhd's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XKLS:7148 vs ZTS, UTHR, VTRS: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duopharma Biotech Bhd Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Duopharma Biotech Bhd's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duopharma Biotech Bhd (XKLS:7148) has a Debt-to-Equity of 0.64 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Duopharma Biotech Bhd and its competitors. This is 19% above median its historical median of 0.54. Over the past decade, Duopharma Biotech Bhd's Debt-to-Equity has ranged from 0.24 to 0.87. According to the industry distribution chart, Duopharma Biotech Bhd ranks #621 out of 812 companies in the Drug Manufacturers industry, placing it in the top 76.5%.
Is Duopharma Biotech Bhd's Debt-to-Equity too high?
Duopharma Biotech Bhd's current Debt-to-Equity of 0.64 is 19% above median its 10-year median of 0.54. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 0.87. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Duopharma Biotech Bhd's value of 0.64 is 137% above this industry median. Based on the distribution chart, Duopharma Biotech Bhd ranks #621 out of 812 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Duopharma Biotech Bhd has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Duopharma Biotech Bhd's Debt-to-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Duopharma Biotech Bhd ranks #621 out of 812 companies for Debt-to-Equity. This places Duopharma Biotech Bhd in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Duopharma Biotech Bhd's value of 0.64 is 137% above this benchmark. Historically, Duopharma Biotech Bhd's own Debt-to-Equity has ranged from 0.24 to 0.87 over the past decade. While the company's 10-year median is 0.54 vs. the industry median of 0.27, Duopharma Biotech Bhd has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Duopharma Biotech Bhd's current Debt-to-Equity of 0.64 is 137% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Duopharma Biotech Bhd and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duopharma Biotech Bhd's current Debt-to-Equity is 0.64, which is 19% above median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duopharma Biotech Bhd stock overvalued right now?
Based on GuruFocus' analysis, Duopharma Biotech Bhd (XKLS:7148) is currently considered Modestly Undervalued. The stock's GF Value™ is RM1.55, compared to a current price of RM1.22 — trading 21.3% below its estimated fair value. The current Debt-to-Equity is 0.64, which is 19% above median its 10-year median of 0.54 and 137% above the Drug Manufacturers industry median of 0.27. Duopharma Biotech Bhd's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Duopharma Biotech Bhd (XKLS:7148), the current Debt-to-Equity is 0.64 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Duopharma Biotech Bhd (XKLS:7148) Overvalued in 2026?
Based on GuruFocus' analysis, Duopharma Biotech Bhd stock appears to be undervalued.
The current stock price of RM1.22 is trading 21.3% below its estimated GF Value™ of RM1.55.
GuruFocus considers Duopharma Biotech Bhd to be Modestly Undervalued.
Key valuation signals for XKLS:7148:
Debt-to-Equity: 0.64 (19% above median its 10-year median of 0.54)
GF Value™: RM1.55 vs. price of RM1.22 (21.3% below fair value)
Industry Position: 137% above the Drug Manufacturers median (#621 of 812)
No single metric tells the full story. See the XKLS:7148 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. The company develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer, and exporter of pharmaceutical products and medicines. Geographically, the company generates the majority of its revenue from Malaysia.
79GF Score
Get the complete analysis for XKLS:7148
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKLS:7148 has been successfully added to your 
